Phase I study of combination chemotherapy with irinotecan hydrochroride(CPT-11) and nedaplatin(NDP) for locally advanced stage Ib2-IVa cervical cancer after Concurrent chemoradiotherapy (CCRT)

Trial Profile

Phase I study of combination chemotherapy with irinotecan hydrochroride(CPT-11) and nedaplatin(NDP) for locally advanced stage Ib2-IVa cervical cancer after Concurrent chemoradiotherapy (CCRT)

Discontinued
Phase of Trial: Phase I

Latest Information Update: 12 May 2016

At a glance

  • Drugs Irinotecan (Primary) ; Nedaplatin (Primary)
  • Indications Cervical cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Oct 2013 Planned End Date changed from 1 Jul 2015 to 31 Dec 2013 as reported by University Hospital Medical Information Network - Japan.
    • 07 Oct 2013 Status changed from recruiting to discontinued as reported by University Hospital Medical Information Network - Japan.
    • 13 Mar 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top